Bank Of Montreal

Direxion Daily Small Cap Bull 3X ETF

SPDR S&P Retail ETF

ProShares UltraPro Dow30

ProShares UltraShort Bloomberg Natrl Gas

Guggenheim Solar ETF

Direxion Technology Bear 3X Shares

Materials Select Sector SPDR

ProShares Trust ProShares Short Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF

Direxion Daily Small Cap Bear 3X ETF

ProShares Ultra Bloomberg Natural Gas

Direxion Daily Technology Bull 3X ETF

ARK Innovation ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Magal Security Systems Ltd.

Direxion Financial Bear 3X Shar

Direxion Daily Semicondct Bull 3X ETF

JELD-WEN Holding Inc. Common Stock

Las Vegas Sands Corp. Common Stock

Century Communities Inc. Common Stock

Kontoor Brands Inc. Common Stock

Bath & Body Works Inc.

RLJ Lodging Trust Common Shares of Beneficial Interest $0.01 par value

Leggett & Platt Incorporated Common Stock

Snap Inc. Class A Common Stock

Cleveland-Cliffs Inc. Common Stock

Civitas Resources Inc. Common Stock

Archer Aviation Inc. Class A Common Stock

AMC Entertainment Holdings Inc. Class A Common Stock

Oklo Inc.

QuantumScape Corporation Class A Common Stock

Sea Limited American Depositary Shares each representing one Class A Ordinary Share

Cameco Corporation Common Stock

Twilio Inc. Class A Common Stock

Spotify Technology S.A. Ordinary Shares

Cloudflare Inc. Class A Common Stock

Molina Healthcare Inc Common Stock

Click here to get full coverage on Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha

Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN)  Seeking Alpha

Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha

Click here to get full coverage on Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  Business Wire

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Click here to get full coverage on Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment?  simplywall.st

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st

Click here to get full coverage on (VRDN) On The My Stocks Page - news.stocktradersdaily.com

(VRDN) On The My Stocks Page  news.stocktradersdaily.com

(VRDN) On The My Stocks Page - news.stocktradersdaily.com

Click here to get full coverage on Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease - Ophthalmology Times

Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease  Ophthalmology Times

Viridian announces topline data from THRIVE-2 phase 3 clinical trial of veligrotug for treatment of thyroid eye disease - Ophthalmology Times

Click here to get full coverage on Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates  Nasdaq

Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq

Click here to get full coverage on Viridian Reports Positive Phase 3 Trial Results - TipRanks

Viridian Reports Positive Phase 3 Trial Results  TipRanks

Viridian Reports Positive Phase 3 Trial Results - TipRanks

Click here to get full coverage on Viridian Therapeutics: Advancing Toward Commercialization with a Diverse Pipeline and Robust Financials - AInvest

Viridian Therapeutics: Advancing Toward Commercialization with a Diverse Pipeline and Robust Financials  AInvest

Viridian Therapeutics: Advancing Toward Commercialization with a Diverse Pipeline and Robust Financials - AInvest

Click here to get full coverage on Stifel maintains Buy on Viridian Therapeutics, $41 target - Investing.com

Stifel maintains Buy on Viridian Therapeutics, $41 target  Investing.com

Stifel maintains Buy on Viridian Therapeutics, $41 target - Investing.com

Click here to get full coverage on Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results  Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results - Business Wire

Click here to get full coverage on Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) (NASDAQ:VRDN) - Seeking Alpha

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) (NASDAQ:VRDN)  Seeking Alpha

Viridian Therapeutics: A Clearer Picture Emerges (Rating Upgrade) (NASDAQ:VRDN) - Seeking Alpha

Click here to get full coverage on Viridian Therapeutics Stockholders Approve Key Proposals - TipRanks

Viridian Therapeutics Stockholders Approve Key Proposals  TipRanks

Viridian Therapeutics Stockholders Approve Key Proposals - TipRanks

Click here to get full coverage on Viridian Therapeutics: A Catalyst-Driven Play on Clinical Triumphs and Strategic Visibility - AInvest

Viridian Therapeutics: A Catalyst-Driven Play on Clinical Triumphs and Strategic Visibility  AInvest

Viridian Therapeutics: A Catalyst-Driven Play on Clinical Triumphs and Strategic Visibility - AInvest

Click here to get full coverage on Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - Business Wire

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED)  Business Wire

Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) - Business Wire

Click here to get full coverage on Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results  Business Wire

Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results - Business Wire

Click here to get full coverage on Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease  Business Wire

Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease - Business Wire

Click here to get full coverage on Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024  Business Wire

Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 - Business Wire

Click here to get full coverage on Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Business Wire

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors  Business Wire

Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors - Business Wire

Click here to get full coverage on Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease  Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease - Business Wire

Click here to get full coverage on Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - Business Wire

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED)  Business Wire

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - Business Wire

Click here to get full coverage on Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire

Viridian Therapeutics to Participate in Upcoming June Investor Conferences  Business Wire

Viridian Therapeutics to Participate in Upcoming June Investor Conferences - Business Wire

Click here to get full coverage on Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews

Pre-market Movers: EWTX, TNXP, LNSR, VRDN...  RTTNews

Pre-market Movers: EWTX, TNXP, LNSR, VRDN... - RTTNews

Click here to get full coverage on Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease  Business Wire

Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease - Business Wire

Click here to get full coverage on Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Where are the Opportunities in (VRDN)  news.stocktradersdaily.com

Where are the Opportunities in (VRDN) - news.stocktradersdaily.com

Click here to get full coverage on Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Viridian Therapeutics Announces Inducement Stock Option Grants  Nasdaq

Viridian Therapeutics Announces Inducement Stock Option Grants - Nasdaq

Click here to get full coverage on Viridian Therapeutics appoints Jeff Ajer to board - Investing.com

Viridian Therapeutics appoints Jeff Ajer to board  Investing.com

Viridian Therapeutics appoints Jeff Ajer to board - Investing.com

Click here to get full coverage on Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Viridian Therapeutics, Inc.\DE SEC 10-K Report  TradingView

Viridian Therapeutics, Inc.\DE SEC 10-K Report - TradingView

Click here to get full coverage on Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Clinical Trials Arena

Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints  Clinical Trials Arena

Viridian Therapeutics’ stock jumps after Phase III trial met all endpoints - Clinical Trials Arena

Click here to get full coverage on Viridian Therapeutics Trying To Close In On Key Technical Benchmark - Investor's Business Daily

Viridian Therapeutics Trying To Close In On Key Technical Benchmark  Investor's Business Daily

Viridian Therapeutics Trying To Close In On Key Technical Benchmark - Investor's Business Daily

Click here to get full coverage on Viridian Therapeutics Q1 2025 Financial Results - TradingView

Viridian Therapeutics Q1 2025 Financial Results  TradingView

Viridian Therapeutics Q1 2025 Financial Results - TradingView

Click here to get full coverage on Viridian Therapeutics at Jefferies Conference: Strategic Advancements in TED - Investing.com

Viridian Therapeutics at Jefferies Conference: Strategic Advancements in TED  Investing.com

Viridian Therapeutics at Jefferies Conference: Strategic Advancements in TED - Investing.com

Click here to get full coverage on Notable Monday Option Activity: HUN, RIVN, VRDN - Nasdaq

Notable Monday Option Activity: HUN, RIVN, VRDN  Nasdaq

Notable Monday Option Activity: HUN, RIVN, VRDN - Nasdaq

Click here to get full coverage on A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $19 to $41 - 富途牛牛

A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $19 to $41  富途牛牛

A Quick Look at Today's Ratings for Viridian Therapeutics(VRDN.US), With a Forecast Between $19 to $41 - 富途牛牛

Click here to get full coverage on Viridian Therapeutics earnings beat by $0.11, revenue topped estimates - Investing.com

Viridian Therapeutics earnings beat by $0.11, revenue topped estimates  Investing.com

Viridian Therapeutics earnings beat by $0.11, revenue topped estimates - Investing.com

Click here to get full coverage on B.Riley maintains Viridian stock Neutral, $19 target - Investing.com

B.Riley maintains Viridian stock Neutral, $19 target  Investing.com

B.Riley maintains Viridian stock Neutral, $19 target - Investing.com

Click here to get full coverage on Viridian Therapeutics appoints new director, sees board resignation - Investing.com

Viridian Therapeutics appoints new director, sees board resignation  Investing.com

Viridian Therapeutics appoints new director, sees board resignation - Investing.com

Click here to get full coverage on Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - Business Wire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock  Business Wire

Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock - Business Wire

Click here to get full coverage on Viridian completes subject enrolment for Phase III trial of TED treatment - Clinical Trials Arena

Viridian completes subject enrolment for Phase III trial of TED treatment  Clinical Trials Arena

Viridian completes subject enrolment for Phase III trial of TED treatment - Clinical Trials Arena

Click here to get full coverage on Viridian Therapeutics Appoints Jeff Ajer to Board - TipRanks

Viridian Therapeutics Appoints Jeff Ajer to Board  TipRanks

Viridian Therapeutics Appoints Jeff Ajer to Board - TipRanks

Click here to get full coverage on Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED - insights.citeline.com

Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED  insights.citeline.com

Viridian’s Veligrotug Poses Formidable Challenge For Amgen’s Tepezza In TED - insights.citeline.com

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on Viridian Therapeutics announces plans for clinical trial program evaluating VRDN-003 in TED treatment - Ophthalmology Times

Viridian Therapeutics announces plans for clinical trial program evaluating VRDN-003 in TED treatment  Ophthalmology Times

Viridian Therapeutics announces plans for clinical trial program evaluating VRDN-003 in TED treatment - Ophthalmology Times

Click here to get full coverage on Viridian Therapeutics chooses VRDN-003 as lead subcutaneous therapy for Thyroid Eye Disease - Ophthalmology Times

Viridian Therapeutics chooses VRDN-003 as lead subcutaneous therapy for Thyroid Eye Disease  Ophthalmology Times

Viridian Therapeutics chooses VRDN-003 as lead subcutaneous therapy for Thyroid Eye Disease - Ophthalmology Times

Click here to get full coverage on Viridian Thrives on phase III with veligrotug in thyroid eye - BioWorld MedTech

Viridian Thrives on phase III with veligrotug in thyroid eye  BioWorld MedTech

Viridian Thrives on phase III with veligrotug in thyroid eye - BioWorld MedTech

Click here to get full coverage on VIRIDIAN METALS ANNOUNCES INTENTION TO DELIST FROM THE TSXV AND LIST ON THE CSE - PR Newswire Canada

VIRIDIAN METALS ANNOUNCES INTENTION TO DELIST FROM THE TSXV AND LIST ON THE CSE  PR Newswire Canada

VIRIDIAN METALS ANNOUNCES INTENTION TO DELIST FROM THE TSXV AND LIST ON THE CSE - PR Newswire Canada

Click here to get full coverage on Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year (NASDAQ:VRDN) - Seeking Alpha

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year (NASDAQ:VRDN)  Seeking Alpha

Viridian Therapeutics: Key Catalysts Coming In The Second Half Of The Year (NASDAQ:VRDN) - Seeking Alpha

Click here to get full coverage on Viridian announces positive data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients diagnosed with chronic TED - Ophthalmology Times

Viridian announces positive data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients diagnosed with chronic TED  Ophthalmology Times

Viridian announces positive data from ongoing Phase 1/2 trial evaluating VRDN-001 in patients diagnosed with chronic TED - Ophthalmology Times

Click here to get full coverage on Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment - Clinical Trials Arena

Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment  Clinical Trials Arena

Viridian Therapeutics to begin Phase III trials of thyroid eye disease treatment - Clinical Trials Arena

Click here to get full coverage on Viridian looks over Horizon after eye disease med notches early improvements - Fierce Biotech

Viridian looks over Horizon after eye disease med notches early improvements  Fierce Biotech

Viridian looks over Horizon after eye disease med notches early improvements - Fierce Biotech

Click here to get full coverage on Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 (VRDN) - Seeking Alpha

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 (VRDN)  Seeking Alpha

Viridian Therapeutics: Disconnect Between Fundamentals And Share Price In 2023 (VRDN) - Seeking Alpha

Click here to get full coverage on Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - Business Wire

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)  Business Wire

Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) - Business Wire

Click here to get full coverage on Viridian discloses FcRn inhibitors VRDN-006 and VRDN-008 - BioWorld MedTech

Viridian discloses FcRn inhibitors VRDN-006 and VRDN-008  BioWorld MedTech

Viridian discloses FcRn inhibitors VRDN-006 and VRDN-008 - BioWorld MedTech

Click here to get full coverage on Stifel Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq

Stifel Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation  Nasdaq

Stifel Initiates Coverage of Viridian Therapeutics (VRDN) with Buy Recommendation - Nasdaq

Click here to get full coverage on Viridian receives FDA consent to run Phase I thyroid eye disease trial - Clinical Trials Arena

Viridian receives FDA consent to run Phase I thyroid eye disease trial  Clinical Trials Arena

Viridian receives FDA consent to run Phase I thyroid eye disease trial - Clinical Trials Arena

Click here to get full coverage on Viridian Therapeutics - The Pharma Letter

Viridian Therapeutics  The Pharma Letter

Viridian Therapeutics Inc (VRDN)

Price Chart

Key Statistics

Technicals

About VRDN

Latest News

Viridian Therapeutics: The Song Remains The Same (NASDAQ:VRDN) - Seeking Alpha

Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Is Viridian Therapeutics (NASDAQ:VRDN) A Risky Investment? - simplywall.st

Advanced Charts

Top Gainers

Top Losers